This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Mylan-Pfizer’s Upjohn deal will result in limited overlap, vertical integration, companies tell CADE

By Ana Paula Candil ( January 13, 2020, 22:20 GMT | Insight) -- Global pharma company Mylan and Pfizer's off-patent drug business, Upjohn, have told the Brazilian competition authority that their deal will result in a limited overlap in the market for atypical antipsychotics, used to treat psychiatric conditions, and in a vertical integration between Mylan's supply of active pharmaceutical ingredients and Upjohn's future production of certain medicines. Global pharma companies Mylan and Pfizer, who have agreed to a deal involving Pfizer's Upjohn, have told the Brazilian competition authority that the transaction will result in a limited overlap in the market for atypical antipsychotics, used to treat psychiatric conditions, and in a vertical integration between Mylan's supply of active pharmaceutical ingredients and Upjohn's future production of certain medicines....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login